Novartis

NATALEE-TRIO033

NCT03701334

A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

Status:

Closed to Accrual

26459-200.png

III

Phase

Line of Therapy.png

Line of Therapy

Disease Stage.png

Early Cancer

Disease Stage

Target.png

Biomarker(s)

HER2-, ER+

Investigational

Product

Ribociclib

Treatment Arms

o Ribociclib + Endocrine Therapy

o Endocrine Therapy